Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Acasti Pharma Inc. ACST NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • CA • USD

SharesGrow Score
40/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Acasti Pharma Inc. (ACST) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 3 Buy, 2 Hold.

ACST Analyst Ratings

Buy
5
Ratings
3 Buy
2 Hold
Based on 5 analysts giving stock ratings to Acasti Pharma Inc. in the past 3 months
Rating breakdown
Buy
3 60%
Hold
2 40%
60%
Buy
3 analysts
40%
Hold
2 analysts
0%
Sell
0 analysts

People Also View

OCGN
OCGN
Ocugen, Inc.
$1.80
+0.56%
 CBIO
CBIO
Catalyst Biosciences, Inc.
$19.52
+8.50%
 TNXP
TNXP
Tonix Pharmaceuticals Holding Corp.
$13.35
+2.85%
 IBIO
IBIO
iBio, Inc.
$2.19
-0.45%
 ADXS
ADXS
Advaxis, Inc.
$0.60
+0.00%
 ONTX
ONTX
Onconova Therapeutics, Inc.
$1.00
-0.47%
 ABVC
ABVC
ABVC BioPharma, Inc.
$1.36
-1.45%
 DFFN
DFFN
Diffusion Pharmaceuticals Inc.
$4.40
+10.28%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message